A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD
Phase of Trial: Phase IV
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Umeclidinium/vilanterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 16 Jun 2016 Status changed from active, no longer recruiting to completed.
- 19 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 19 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.